869001-84-3

Upstream product

• 147-85-3 L-proline 
• 220200-89-5 (2R,5R)-5-benzyl-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 
• 118916-60-2 (2R,5S)-2-trichloromethyl-1-aza-3-oxabicyclo[3.3.0]octan-4-one 

Downstream Products

• 869002-01-7 di-tert-butyl N-tert-butyloxycarbonyl-glycyl-L-2-benzylprolyl-L-glutamate 
• 869001-92-3 N-tert-butyloxycarbonyl-glycyl-L-2-benzylproline 

Relevant academic research and scientific papers

ANALOGS OF GLYCYL-PROLYL-GLUTAMATE

Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson''s disease.

Synthesis of proline-modified analogues of the neuroprotective agent glycyl-L-prolyl-glutamic acid (GPE)

The synthesis of ten proline-modified analogues of the neuroprotective tripeptide GPE is described. Five of the analogues incorporate a proline residue with a hydrophobic group at C-2 and two further analogues have this side chain locked into a spirolactam ring system. The pyrrolidine ring was also modified by replacing the γ-CH2 group with sulfur and/or incorporation of two methyl groups at C-5.